Palvella Therapeutics, Inc. Common Stock
PVLAStock
$147.77+448.63%52W
Market Cap$2.12B
P/E—
Div yield—
Beta-0.21
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)40.96%
Price vs S&P 500 (4W)37.41%
VGM Score41.78
Market Capitalization$2.12B
Earnings Surprise History
Q1 26-1.20est. -0.95
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.23
4.23
4.26
4.23
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PVLAPalvella Therapeutics, Inc. Common Stock | F | D | A | $147.77 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Palvella Therapeutics is a late-stage biopharmaceutical company developing treatments for rare genetic skin diseases that currently lack approved therapies. The company's lead candidate, QTORIN rapamycin gel, is based on its proprietary QTORIN platform and is in clinical development for two rare genetic skin disorders.